C. Difficile

Prior to this study’s publication, the literature about pediatric C diff infection was limited.

The quick Pitt Bacteremia Score offers accuracy comparable to the original version's across multiple infections, and maintains ease of use.

Bezlotoxumab, a human monoclonal anti­body directed against Clostridioides diffi­cile toxin B, is currently indicated for the prevention of recurrent C diffi­cile infection

In 2017, a guideline update stripped metronidazole of its first-line therapy designation and crowned oral vancomycin as initial therapy for all C difficile infection cases.

DNA methyltransferase, an epigenetic process, has been found to mediate sporulation and pathogenesis in C diff.

The CDC’s plan calls for 30% reduction in C diff infections, but work remains to be done.

An observational study suggests that oral vancomycin may be associated with earlier symptom resolution than metronidazole for children hospitalized with non-severe C diff infections.

Agency’s annual report on healthcare-associated bugs highlights reduced incidence of CLABSI, CAUTI, and C diff.

Rates of health care facility-acquired C diff seemed to show improvement, but understanding community-acquired cases better in the future can help aid prevention efforts.

After receiving FMT capsules containing drug resistant ESBL E coli, 2 patients developed severe illness with 1 patient death.

Eravacycline may be an option for patients with a history of C diff or those with a history of infections who are at risk for developing the infection.

When guidelines are quickly implemented for C diff treatment recommendations, the changes are reflected quickly.

Use of high-risk antibiotics is linked to C diff infections, but the class of antibiotics with the strongest link has changed over time underscoring the need for ongoing assessment.

A hospital sheds light on how dogs can help identify C diff contamination.

Can UV disinfecting lights tackle health care-associated infections?

A new study using shotgun metagenomic sequencing found that FMT yielded a sustained decrease in antimicrobial resistance genes and potential pathogens in children with recurrent C diff.

Not all disinfectants are created equal and here's why we need to remember that.

A new study evaluates timelines for C diff treatment, diagnosis, and isolation.

Recent patient death calls into question viability of effective treatment for recurrent C diff.

This warning comes after the FDA was made aware of bacterial infections caused by multidrug-resistant organisms have occurred following transmission during FMT.

At MAD-ID 2019, Alison Lew, PharmD, spoke about her research on oral vancomycin prophylaxis to reduce CDI recurrence.

A study found that patients with complicated C diff infections were more likely to have been previously hospitalized with numerically less time between hospitalization and recent C diff episode.

The authors of a new study say the use of antibiotics and proton pump inhibitors are among the list of risk factors for recurring C diff infections.

A new review recommends updated guidelines for diagnosing and managing Candida and C diff coinfection.

Vanessa Stevens, PhD, discusses her research on fluoroquinolone and cephalosporin prescribing and rates of Clostridium difficile infections at VA health care facilities.

Investigators from the University of Sherbrooke found some bacterial strains of C diff are likely associated with mortality in C diff infection, specifically, NAP1/BI/R027.

Contagion® caught up with Christian Lillis, executive director of the Peggy Lillis Foundation, to hear about the organization’s recent efforts, what obstacles it’s facing, and how providers can help.

The study found that that acute care hospitals with a 20% reduction in fluoroquinolone or third and fourth generation cephalosporins had a “corresponding decrease” in hospital-onset C diff.

Clostridium difficile rates in stem cell transplant patients are approximately 9 times greater than in hospitalized patients, with rates about twice as high in allogeneic vs autologous transplants.

The US Food and Drug Administration has granted Breakthrough Therapy Designation to investigational drug CP101 for the treatment of patients with recurrent C diff infection.